checkAd

     335  0 Kommentare Valneva Reports FY 2020 Cash of Over €200 Million - Seite 3

    [1] Valneva Reports Nine Month Results Marked by Further Major Corporate Achievements

    2 Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15

    [3] Valneva Announces Major COVID-19 Vaccine Partnership with U.K. Government

    4 Valneva Announces New $85 Million Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed

    Lesen Sie auch

    Attachment


    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    2 im Artikel enthaltene WerteIm Artikel enthaltene Werte
    Valneva Reports FY 2020 Cash of Over €200 Million - Seite 3 FY 2020 cash and cash equivalents of €204.4 million, exceeding guidance of between €180 million and €200 million1FY 2020 cash and cash equivalents include $130 million from the Lyme disease collaboration with Pfizer2 and €96.7 million from the UK …